GH Research PLC (GHRS)
NASDAQ: GHRS · Real-Time Price · USD
12.10
0.00 (0.00%)
Aug 8, 2025, 9:35 AM - Market open

Revance Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202020
Period Ending
Aug '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2020
7513643025061,214-
Upgrade
Market Cap Growth
24.64%20.71%-40.33%-58.34%--
Upgrade
Enterprise Value
44317174249933-
Upgrade
Last Close Price
12.107.005.809.7223.33-
Upgrade
PB Ratio
2.472.041.382.024.38-
Upgrade
P/TBV Ratio
2.482.041.382.024.38-
Upgrade
Debt / Equity Ratio
0.000.000.00---
Upgrade
Quick Ratio
29.2516.8724.1536.53100.7023.99
Upgrade
Current Ratio
29.4917.2324.4937.08101.8024.03
Upgrade
Return on Equity (ROE)
-16.35%-19.58%-15.18%-8.52%-6.51%-14.70%
Upgrade
Return on Assets (ROA)
-12.73%-15.15%-10.72%-7.18%-6.60%-8.69%
Upgrade
Return on Capital (ROIC)
-13.16%-15.72%-10.97%-7.28%-6.67%-9.19%
Upgrade
Earnings Yield
-5.46%-10.70%-11.79%-4.44%-0.76%-
Upgrade
FCF Yield
-5.38%-11.62%-11.08%-5.20%-1.27%-
Upgrade
Buyback Yield / Dilution
-8.99%-0.01%-0.00%-19.09%-54.03%-1.28%
Upgrade
Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q